On March 23, Pfizer issued a press release announcing that a new Lyme disease vaccine candidate has demonstrated “strong ...

Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in ...

Pfizer Inc PFE shares are dipping on Tuesday. The company announced a series of settlement agreements that extend the effective U.S. patent life of Vyndamax, its treatment for transthyretin‑mediated ...

Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...

The MarketWatch News Department was not involved in the creation of this content. -- Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals ...

Lyme disease is the most common tick-borne infectious disease in the United States. There is no vaccine to protect against it in humans. Biopharmaceutical company Pfizer and Valne ...

Paying Patients to Access the Nation’s #1 Prescribed Oral Blood ThinnerPRINCETON, N.J.--(BUSINESS WIRE)--$BMY #Eliquis--The Bristol Myers Squibb-Pfizer (BMS NYSE: BMY) — (Pfizer NYSE: PFE) Alliance ...

Pfizer continues delivering consistent earnings beats, driven by cost-cutting initiatives and improving margins. Learn more ...

Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above The investigational vaccine candidate was well tolerated ...